

25

van Diemen H A, Polman C H, van Dongen M M, Nauta J J, Strijers R L, van Loenen A C, Bertelsmann F W, Koetsier J C. 4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. *J Neurol Sci* 1993; 116: 220–226.

Yamaguchi S and Rogawski M A (1992): Effects of anti-convulsant drugs on 4-aminopyridine-induced seizures in mice. *Epilepsy Res.* 11:9–16.

Patents:

Effland R C, Klein J T, Davis K L Olsen G E; U.S. Pat. No. 4,970,218 entitled "N-(Pyridinyl)-1H-indol-1-amines".

Hansebout R R and Blight A R; U.S. Pat. No. 5,545,648 entitled "Use of 4-aminopyridine in the reduction of chronic pain and spasticity in a spinal cord injured patient".

Hansebout R R and Blight A R; WO 94/14439 entitled "The use of 4-aminopyridine in the treatment of a neurological condition".

Huger, F. P., Kongsamut, S., C. P. Smith & L. Tang. U.S. Pat. No. 5,776,955 entitled "Use of unsubstituted and substituted N-(pyrrol-1-yl) pyridinamines as anticonvulsant agents".

Kongsamut, S., C. P. Smith & A. T. Woods; U.S. Pat. No. 5,356,910 entitled "Use of N-(Pyridinyl)-1H-indol-1-amines for the Treatment of Obsessive Compulsive Disorder".

Kongsamut, S., C. P. Smith & A. T. Woods; U.S. Pat. No. 5,356,910 entitled "Use of N-(Pyridinyl)-1H-indol-1-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders".

Masterson J G and Myers M; U.S. Pat. No. 5,370,879 entitled "Formulations and their use in the treatment of neurological diseases".

Masterson J G and Myers M; U.S. Pat. No. 5,580,580 entitled "Formulations and their use in the treatment of neurological diseases".


Masterson J G and Myers M; U.S. Pat. No. 5,540,938 entitled "Formulations and their use in the treatment of neurological diseases".

Wurtman R J and Buyukysal R; WO 89/09600 entitled "Method and composition for treating neurological disorders".

We claim:

1. A method of treating Bladder Irritation said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I

26



wherein

m is 0, 1 or 2;

n is 0, 1 or 2;

p is 0 or 1;

each R is independently hydrogen, halogen, trifluoromethyl, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, benzyloxy, hydroxy, nitro or amino;


each R<sub>1</sub> is independently hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkenyl, C<sub>1</sub>-C<sub>6</sub>alkanoyl, halogen, cyano, —C(O)C<sub>1</sub>-C<sub>6</sub>alkyl, —C<sub>1</sub>-C<sub>6</sub>alkyleneCN, —C<sub>1</sub>-C<sub>6</sub>alkyleneNR'R" wherein R' and R" are each independently hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl, —C<sub>1</sub>-C<sub>6</sub>alkyleneOC(O)C<sub>1</sub>-C<sub>6</sub>alkyl, or —CH(OH)R<sub>4</sub> wherein R<sub>4</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl;

R<sub>2</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl optionally substituted with halogen, hydroxy or benzyloxy, C<sub>1</sub>-C<sub>6</sub>alkenyl, C<sub>1</sub>-C<sub>6</sub>alkynyl, —CO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, or —R<sub>5</sub>—NR'R" wherein R<sub>5</sub> is C<sub>1</sub>-C<sub>6</sub>alkylene, C<sub>1</sub>-C<sub>6</sub>alkenylene or C<sub>1</sub>-C<sub>6</sub>alkynylene and R' and R" are each independently hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl or alternatively the group —NR'R" as a whole is 1-pyrrolidinyl; and

R<sub>3</sub> is hydrogen, nitro, amino, halogen, C<sub>1</sub>-C<sub>6</sub>alkoxy, hydroxy or C<sub>1</sub>-C<sub>6</sub>alkyl

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein the compound has the following formula:



\* \* \* \* \*